CSL reports Phase III rIX-FP data

The CSL Behring subsidiary of CSL Ltd. (ASX:CSL) said three open-label Phase III trials of Factor IX-albumin fusion protein ( rIX-FP) to treat hemophilia B met their primary endpoints. Data were presented at the International Society of Thrombosis and Haemostasis Congress in Toronto.

The first trial compared the effects of rIX-FP in two treatment groups. One received on-demand treatment for six months, then switched to prophylactic treatment every seven days. The other received prophylactic treatment every seven days for six months, then switched to prophylactic treatment every 10 or 14 days for 12-18 months. ...